Capricor Therapeutics Stock Rises Above 50-Day Average

Analysts Weigh In on What's Next for the Biotech Firm

Mar. 31, 2026 at 7:12am

Got story updates? Submit your updates here. ›

Shares of Capricor Therapeutics (NASDAQ:CAPR) have risen above their 50-day moving average, sparking analyst commentary on the biotech company's future prospects. The stock hit a high of $29.27 on Monday before closing at $27.77, with over 745,000 shares traded.

Why it matters

Capricor Therapeutics is a clinical-stage biotech focused on developing cell and exosome-based therapies for cardiovascular and rare diseases. The stock's rise above its 50-day average is seen as a positive technical indicator, potentially signaling increased investor interest and momentum.

The details

Several Wall Street analysts have issued reports on Capricor Therapeutics in recent months. Piper Sandler reissued an 'overweight' rating and raised its price target to $58, while HC Wainwright reiterated a 'buy' rating with a $60 price objective. Other firms like iA Financial and Alliance Global Partners have also maintained bullish stances on the stock.

  • Capricor Therapeutics' stock price crossed above its 50-day moving average of $26.80 during trading on Monday, March 31, 2026.
  • The stock hit an intraday high of $29.27 on March 31, 2026 before closing at $27.77.

The players

Capricor Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases. The company is headquartered in Beverly Hills, California.

Piper Sandler

An investment bank that has issued an 'overweight' rating and $58 price target on Capricor Therapeutics.

HC Wainwright

An investment firm that has reiterated a 'buy' rating with a $60 price objective on Capricor Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Analysts will be closely watching to see if Capricor Therapeutics can maintain its momentum and continue trading above the key 50-day moving average level.

The takeaway

Capricor Therapeutics' stock surge above its 50-day average reflects growing investor optimism around the company's pipeline of cell and exosome-based therapies targeting cardiovascular and rare diseases. The positive analyst commentary suggests the biotech firm may have more upside potential if it can deliver on its clinical development milestones.